RBC Reiterates Outperform Rating on Eli Lilly, Keeps $1,500 Target
RBC Capital reiterated its Outperform rating on Eli Lilly and a $1,500 price target. The target implies 27.2% upside from the Oct. 9 close of $1,179.27.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
TD Cowen reiterates Buy rating on Eli Lilly, $1250 target
TD Cowen reiterated a Buy rating on Eli Lilly with a $1250 price target, implying 7.3% upside versus the Sep 21 close of $1164.89.
TD Cowen reiterates Outperform on Eli Lilly; $1,250 target
TD Cowen reiterated an Outperform rating on Eli Lilly (LLY) and set a $1,250.00 price target, implying 7.3% upside versus the Sep 21 close of $1,164.89.
Eli Lilly Could Swing Over $76 Billion In Value After Earnings
Earnings season will likely keep the tape jumpy this week, and the options market is already sketching out where the biggest post-print air pockets — and upside gaps — could show up, according to Pro. This is a -selected watchlist that runs from large-cap healthcare to high-beta software and storage names. The marquee
LLY rating reiterated
Leerink reiterates Eli Lilly stock rating due to progress in gene therapy. This may impact investor sentiment on the stock.